Deep brain drug-delivery control using vagus nerve communications by Donohoe, Michael et al.
Deep Brain Drug-delivery Control using Vagus Nerve Communications
Michael Donohoea,∗, Brendan Jenningsa, Sasitharan Balasubramaniam1
aTelecommunications Software & Systems Group (TSSG), Waterford Institute of Technology, Ireland
Abstract
Vagus nerve stimulation (VNS) uses electrical impulses applied at the neck in order to mitigate the effects of, for
example, epileptic seizures. We propose using VNS to provide data pulses to communicate with a drug-delivery
system embedded near the brainstem. We model the generation of a vagus nerve compound action potential (CAP),
calculating the signal attenuation and the resulting transmission range. The metabolic cost of CAP transmission in
terms of the use of adenosine triphosphate (ATP) is also calculated. The channel capacity for on-off keying (OOK) is
computed from the CAP characteristics, the neural refractory period and the level of background neural noise. The
resulting low bit-rate, unidirectional asynchronous transmission system is analysed for the use of different methods of
forward error correction (FEC) to improve bit-error rate (BER). We show a proposed data packet structure that could
deliver instructions to an embedded drug-delivery system with multiple addressable drug reservoirs. We also analyse
the scope for powering the drug-delivery system with energy harvested from cerebrospinal glucose.
Keywords: Vagus Nerve, Compound Action Potential, Neural Transmission, Forward Error
Correction
1. Introduction
Communicating with powered implants embedded in the human body, such as cardiac pacemakers or defibrillators,
is an increasingly important part of medical treatment. Wireless communications systems provide a bidirectional
flexible link over short ranges [1], but place power requirements of hundreds of microwatts on an implant [2]. Apart
from the power requirements, the transmission of commands from an external wireless electromagnetic (EM) module
to an implanted device does create security implications and may be subject to hacking [3]. An alternative method is
to use the peripheral or cranial nervous system in the body to transport data commands from a transmitter at one point
on a nerve to an embedded receiver at another point. The use of neural communications is part of wider research into
implanted devices at the micro and nano level [4] where restrictions in antenna size will limit the use of EM systems.
Data communications using action potentials (AP) along a single neuronal axon is proposed by Parcerisa-Giné
and Akyildiz [5] as an option for providing a physical link between embedded micro devices. Channel models for
communications using neural spikes (APs) and neurotransmitters between hippocampal neurons have been developed
by Malak and Akan [6], Ramezani and Akan [7] and Veletić et al [8]. Data communications through the single median
giant axon of the earthworm was modelled by Abbasi et al [9] who calculated a data throughput based on four different
stimulus frequencies, with each frequency representing two bits of information. A neuron channel model using a sub-
threshold (non-spiking) stimulus was proposed by Khodaei and Pierobon [10] [11], though sub-threshold impulses
have a very short range along an axon [12]. Single neurons are, however, difficult to access and the placement of
transmitters and receivers would be particularly challenging. Consequently, it could be more practical to examine the
collective stimulus of multiple neurons forming a compound action potential (CAP) to provide a neural data pulse.
There is ongoing research into the use of vagus nerve stimulation (VNS) for the treatment of epileptic seizures
[13], depression, heart failure [14], arthritis [15] and Crohn’s disease. At present a VNS system relies on human
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intervention by the physician and patient to programme the duration and intensity of the stimulus pulses. A more
flexible biofeedback system is proposed by Ward et al [16] using the degree of measured nerve activation to control
stimulus delivery and provide a personalised stimulus profile. Non-stimulus based therapies include drug-delivery to
the brain, although the protective blood-brain barrier (BBB) presents a challenge for the absorption of drugs [17] to
treat, for example, cancer tumours. A drug-delivery system for treating epilepsy is described by Salam et al [18] with
embedded electrodes to detect seizures and a micromechanical pump to deliver the drug from a refillable reservoir
located under the scalp. A neural probe with an electrophoretic microfluidic ion pump is proposed by Proctor et
al [19] to deliver variable doses of a single drug across an ion-exchange membrane. Another release mechanism is
electrothermal membrane activation, first proposed by Santini et al [20], where a metallic membrane covers a drug
reservoir. An electrical current ruptures the membrane by heating and the drug reservoir releases its contents. Either
of these delivery systems could be controlled by a local processor and receive release commands from an external
source along a neural pathway.
Power could be delivered to an implanted device by a long-life battery [21], although this would have to be
replaced at regular intervals, requiring repeated surgical intervention. The alternative is to use some form of energy
harvesting to power the implant directly or to recharge a battery. Ultrasound energy harvesting operates at shallow
skin depths and will not penetrate through the bone of the skull. It is possible to power implants wirelessly with (i)
near-field short-range EM inductive resonant coupling using coiled antennas at frequencies up to 20 MHz, (ii) mid-
field coupling (900 MHz) or (iii) far-field (2.5 GHz) EM powering [22]. The use of EM power harvesting is subject
to technical constraints to meet recommended safety levels and prevent tissue damage through excessive heating [23].






The conductivity of the tissue is σ, the density is ρ and the electric field strength is E. The SAR value is expressed
in Watts per kilogram and is averaged over 1 g or 10 g of tissue. In the US the exposure limits for an unrestricted
environment, set by the FCC, are 4W/kg for 10g of tissue in the extremities (hands, wrists, feet, ankles) and 1.6 W/kg
for 1 g of head, neck and trunk tissue. In other jurisdictions the equivalent ICNIRP and IEEE guidelines specify 2
W/kg for 10 g of head, neck and trunk tissue and 4 W/kg for 10 g of any other limbs [24]. The SAR limits can be
converted to power intensities at different frequency ranges and a typical value is 2 W/m2 for up to 200 MHz and 10
W/m2 for frequencies greater than 200 MHz [24]. Powering by EM would also require the wearing of an external
powering source if true mobility was required. Ideally the implanted device should have a long-life biocompatible
power harvesting system that would not have the potential to cause tissue damage and would not depend on external
modules.
In previous work [25] we modelled the use of ultrasound to provide harvested power for subcutaneous nanowire-
based nanodevices. We then extended that work by modelling the use of arrays of coupled nanodevices for selective
neural stimulation [26]. The resulting CAPs were modelled as a data communications system (200 bit/s maximum
rate) using on-off keying (OOK) [27]. Our stimulus and communications system is optimised for nerves that are at a
shallow depth, are not shielded by bone and can be readily accessed for device array implantation.
In this paper we model a specific potential application: the use of neural data pulses transmitted along the vagus
nerve to communicate with a programmable, multi-reservoir, drug-delivery system in the brain as shown in Fig. 1. The
vagus nerve is a cranial nerve extending from the brainstem and branching to thoracic, abdominal and retroperitoneal
organs. The normal neuronal signals serve to moderate functions such as heart rate, breathing and rate of digestion.
Two main trunks (branches), the left and the right, can be accessed either side of the neck. The left branch of the vagus
nerve, where VNS electrodes are normally placed in humans, does not include cardiac branches with motor neurons
and so does not cause cardiac side effects. The main side effects are hoarseness, cough or shortness of breath [13],
with no interference to normal brain function [14].
The neural stimulus system delivers current pulses (> 0.2mA) comparable to those delivered by FDA-approved
vagus nerve stimulation (VNS) systems (0.2 mA to 5 mA). Asynchronous data packets composed of CAPs could
deliver instructions to an embedded device using a unidirectional neural transmission system. Detecting neural data
pulses requires lower power than receiving wireless EM signals. Unidirectional transmission implies that no acknowl-
edgement or resend messages can be sent in the reverse direction. We, therefore, analyse the use of forward error









Figure 1: Vagus nerve transmission path delivering data pulses from the stimulus array to the embedded drug-delivery system.
• A model of the generation and propagation of a stimulated neural CAP along the vagus nerve, which shows that
it is possible to deliver a maximum OOK data rate of 200 bit/s at ranges between 60 mm and 100 mm;
• An evaluation of the metabolic energy cost of CAP generation in terms of the use of adenosine triphosphate
(ATP);
• An analysis of the bit error rate (BER) and the coding gain using a selection of FEC methods;
• A proposal for simple packet structure for programmable drug-release commands;
• An assessment of the viability of using glucose energy harvesting for powering an implanted drug-delivery
system.
This article is organised as follows: the activation of the vagus nerve is described in §2; the data link protocol
and error correction in §3; the drug-delivery system components, data packet structure and powering in §4; and our
conclusions are presented in §5.
2. Vagus Nerve Stimulation
When a neuron is stimulated, an AP propagates down the neuron’s axon to a terminating synapse [12]. The
AP cycle duration, typically 5 ms, is called the Refractory Period (Tre f ) and a second stimulus applied during this
interval will not result in another action potential. The extracellular action potential or single fibre action potential
(SFAP) is measured on the outside of the neuron with respect to the surrounding extracellular medium. This is smaller
in magnitude (on the order of nanovolts) than the underlying intracellular AP. The CAP is the algebraic sum of
multiple SFAPs arising from the same external stimulus. The magnitude depends on the number of neurons that are
simultaneously activated.




φe j(t − τ j; v j) (2)
where N is the number of active fibres in total in the nerve, φe j is the SFAP of the jth neuron and v j is the SFAP






Table 1: Vagus Nerve Axons in Left Branch
Axon Type Diameter Average Number
(µm)
Aβ 9-12 825
Aβ, Aδ 3-9 2475
Aδ 1-3 13200
where l is the distance travelled and v j is the SFAP velocity. The CAP amplitude will reduce with longitudinal distance
because the underlying, multi-speed, SFAP bi-phasic peaks will progressively start to cancel each other out [28] giving
a reduced summation. This reduction in CAP amplitude with distance is in contrast to the propagation of individual
APs, where signal regeneration along the neuron ensures that the amplitude remains constant.
In our model an external source will convert data into coded ultrasound pulses for transmission to an embedded
nanodevice array [26]. The array converts the ultrasound into electrical pulses to stimulate bundles of neurons (fas-
cicles) in the vagus nerve and create a corresponding stream of modulated CAPs [27]. A receiver implanted at the
brainstem must detect these CAPs, record them and then interpret them as instructions using some decoding algorithm.
The level of current needed to artificially stimulate a neuron will depend on the excitability of the neuron, the
electrode-neuron distance and the stimulus duration. Larger diameter axons require lower stimulus energy than smaller
diameters. Such larger axons have an insulating sheath of myelin and are classed as Aα, Aβ, Aδ and B [29]. The
myelin sheath has regular gaps at intervals of approximately 2 mm, called nodes of Ranvier (typical width of 2 µm),
where the AP is regenerated. These nodes are also the points at which an external stimulus pulse will enter the neuron.
The fascicles of the vagus nerve contain both myelinated and unmyelinated axons [30] usually in the proportion of
20% efferent fibers (sending signals from the brain to the body) and 80% afferent (sensory) fibers (carrying information
from the body to the brain) [14]. The vast majority are small unmyelinated visceral sensory neurons which carry
information from the stomach, intestines, liver, pancreas, and spleen. These are not activated by VNS and would not
be activiated by our neural stimulus system. In an adult there can be an average of 16,500 myelinated axons in the left
branch and 20,000 in the right branch [31]. The diameter of the myelinated axons varies with 80% less than 3 µm,
15% between 3 µm and 9 µm and 5% greater than 9 µm. The distribution of myelinated axons in the left branch of
the vagus nerve, derived in [31], is shown in Table 1. We model a random distribution of 3300 larger diameter axons
(3 µm to 12 µm) as input to (2) to generate vagus nerve CAPs as shown in Fig. 2.
The left vagus nerve is located at a depth of 2-3 cm from the side of the neck. This makes it surgically accessible
for placing an ultrasound harvesting array and stimulating electrode. At present, electrodes used for VNS are placed
at a point on the neck that’s equidistant between the clavicle (collar bone) and the base of the skull. This is equivalent
to a point half way along the cervical spinal section. In an adult the cervical spinal sections have a total approximate
length of 120 mm [32] so our stimulus array will be placed at least 60 mm from the base of the skull and the brain
stem (Fig. 1). A stimulus applied at the neck could travel to the brain and be detected by a receiver. In our model we
will use a maximum range of 100 mm to allow for physiological variation in the distance from the stimulus array in
the neck to the brain stem. Our modelled vagus nerve CAPs are similar in amplitude to therapeutic stimulus CAPs
[33]. A typical epilepsy treatment stimulus cycle is 30 s on and 5 minutes off [13] applied continuously throughout
the day. The CAP data pulse stream will have a much shorter time span (ms) than VNS and this should help minimise
the possibility of side effects.
2.1. Channel Capacity
In our previous work [27] we computed the channel capacity of a typical peripheral nerve (sural nerve) taking
into account (i) CAP attenuation with distance, (ii) the ceiling imposed by the neural refractory period of 5 ms and
(iii) the background normal neural activity. We now calculate the channel capacity of our modelled vagus nerve and
compute the transmission range, subject to these constraints. The CAP attenuation is modelled as a reduction in mean
amplitude, A(z), using an empirical exponential function as follows:
A(z) = Ge−αz. (4)
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Figure 2: Vagus nerve CAP showing amplitude reduction at two different measuring distances.
The empirical parameters G and α have values that depend on the distribution of axon diameters and the number of
activated neurons in the vagus nerve. We assume our multi-neuron path has average white Gaussian noise (AWGN)
with root mean square (rms) values in the range 5 µV to 10 µV [34] [35]. This is in accordance with models for neural
noise based on experimental microneurographic measurements of normal (as opposed to stimulated) CAPs [36] [37].
Some models for single neuron AP generation also assume Gaussian noise [38] though others propose the addition
of some non-Gaussian frequency-dependent noise [39] to provide more accuracy in single-spike capacity and sorting
models. The maximum possible capacity, C bit/s, of a noisy channel with bandwidth U is given by Shannon’s formula:
C = Ulog2(1 + S NR). (5)
The SNR is the ratio between CAP power and noise power and is derived from the rms noise level, σn, and the rms
amplitude of the CAP, A(z)/
√









The SNR will decrease with distance, because of reduced CAP amplitude, and with higher background noise
levels as shown in Fig. 3. The capacity of the vagus nerve can be derived from (5) and (6) using a Nyquist bandwidth
of 100 Hz [40]. This bandwidth is based on the maximum pulse rate of 200/s, limited by the refractory period. The
capacity ceiling of 200 bit/s can be achieved as long as the SNR is greater than or equal to 3 (equivalent to 4.77 dB).
The SNR values at a range of 100 mm are 11 dB (5 µV) and 5 dB (10 µV) so a capacity of 200 bit/s is possible over
all noise levels at all ranges up to 100 mm.
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Figure 3: SNR for vagus nerve CAP.
2.2. Metabolic Energy Requirements
A conventional EM wireless transmission system can increase the transmission range by increasing the signal
power and hence improving the SNR. A wired transmission system can increase the range through the use of regener-
ators to re-shape and amplify digital signals. Our neural transmission system has elements of both wireless and wired
behaviour in that APs are regenerated at each node of Ranvier but the overall CAP is attenuated because of interaction
between the APs. The CAP reaches maximum initial amplitude when all larger diameter neurons are activated. A
further increase in stimulus energy will trigger lower diameter neurons with slower AP velocities and this will in fact
cause greater CAP spreading and a more rapid reduction in amplitude with distance as we showed in previous work
[27].
The metabolic energy needed to create the electrical energy of a CAP can be calculated from the amount of ATP
that must be hydrolised to support APs. During the transmission of an AP, ATP molecules provide energy to sodium
and potassium pumps in the neuron membrane at every node of Ranvier to return the neuron to the resting state. The





where the number of activated neurons is N, the length of the neural transmission path is l, the distance between nodes
of Ranvier is g (typically 2 mm), the number of ATP molecules required per AP at each node of Ranvier is m and
the energy released per ATP molecule is EAP. The ATP hydrolysis energy is about 30.6 kJ/mol or 5 zJ per molecule
[41]. The energy per molecule is often expressed as approximately 12kBT where kB is Boltzmann’s constant and T is
the absolute operating temperature. The number of ATP molecules per AP, per node of Ranvier, ranges from 400 to
800 × 106 [42] and we will use an average of 600 × 106 molecules of ATP.
A plot of ATP energy requirements for a vagus nerve CAP against transmission range is shown in Fig. 4. The ATP
energy requirement is linear and directly proportional to the transmission range (46 nJ/mm). The plot also shows the
decrease in CAP amplitude (voltage) over the same range based on (4). The total number of ATP molecules needed to
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Figure 4: Vagus nerve CAP increase in ATP energy level requirement and decrease in electrical amplitude with distance.
support a CAP for a range of 100 mm is approximately 93 × 1012. This is a small fraction of the estimated total daily
use of 2 × 1026 transient molecules of ATP in the human body [41].
3. Neural Data Link Protocol
The modelled neural CAP communications channel is serial, unidirectional, low bit-rate and therefore suitable for
asynchronous transmission, where the sender and receiver have separate clocks. Asynchronous data link messages
(packets) are of short duration to ensure that the clocks remain closely aligned to each other. A packet usually consists
of a start-bit, a character coded as pulses (usually an 8-bit byte) and a stop-bit. Such a packet would have a length of
10 bits and a transmission time of 50 ms with an overhead-to-data ratio of 2/8 or 25%. The send and receive clocks
are both based on the expected bit rate and can differ by up to 5% without mis-interpreting the last bit of a ten-bit
sequence.
The data packet will deliver instructions to an embedded multi-reservoir drug-delivery system. This can supply
repeated doses of either same drug or a selection of different drugs but is likely to be serially activated one reservoir
at a time. In our model, a single packet could contain, for example, a two-bit release command and up to six bits of
address information (maximum 64 reservoir locations). The number of reservoirs will determine the actual number of
addresses so the packet could be shorter than 8 bits if there are fewer than 64 reservoirs. Alternatively, a wide range
of stored programmes could be activated using an 8-bit command or smaller, though these would all be pre-set with
associated addresses and with no scope for customisation.
3.1. Forward Error Correction
A unidirectional system has no return path for requesting the re-sending of a faulty packet. Error detection and
correction, if required, must therefore be provided within the packet and the receiver. An additional parity bit, or
check bit, can be used to check that the correct number of “1” values has been received but it can not specify the
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Table 2: Error Correction Codes
Code Data Bits Parity Bits Correction
(max.) Potential (bits)
Hamming(7 4 3) 4 3 1
Hamming(15 11 3) 11 4 1
BCH(15 7 5) 7 8 2
BCH(15 5 7) 5 10 3
BCH(31 21 5) 21 10 2
Golay(23 12 7) 12 11 3
BCH(31 16 7) 16 15 3
location of, or change, a faulty data value. There are other methods for forward error correction (FEC) that can locate
and correct faulty bits.
Code repetition is a technique where each bit in a packet of length g bits is sent n = 2t + 1 times, t ≥ 1. The
receiver decodes one bit at a time from the group of n into the single value that occurs most often. This will correct up
to t errors and will extend the total packet length to gn + 2 bits (including the start/stop bits). The transmission time
will increase to (gn + 2)5 ms, based on a refractory period of 5 ms. Code repetition is simple to implement but the
packet length would cause synchronisation challenges between asynchronous transmitter and receiver. Other types of
code add fewer extra bits to the packet and these are now discussed.
Block codes add additional parity bits to a byte using a particular algorithm to form a codeword [43]. Decoding and
correction is carried out by comparing the received codeword with stored standard generated codewords and finding
the closest match. The entire block is decoded at the same time rather than bit-by-bit. Block codes can be classed
as linear or cyclical and include Hamming linear codes, Golay binary code, Bose-Chaudhuri-Hocquenghem (BCH)
cyclic codes, Reed-Solomon (RS) cyclic codes and Turbo Product codes.
Convolutional codes use more complex encoding and decoding methods, using previous bits to encode or decode
subsequent bits and hence have memory, unlike block codes that are memoryless. The codes operate on data streams
rather than blocks and are more computationally intensive. Our model uses short data packets and we will use exam-
ples of block coding on our neural transmission system to study the effect of multiple error detection and correction.
The block code parameters of BCH can be generated from integers m ≥ 3 and t < 2m−1 as follows:
• Codeword length is n = 2m − 1.
• The number of data bits is k ≥ n − mt and the number of added parity bits is n − k ≤ mt.
• The number of errors that can be corrected is t.
• Minimum Hamming distance, dmin ≥ 2t + 1, is a measure of the difference between a received codeword and
the closest stored codeword.
• The number of errors that can be detected is dmin − 1 .
Hamming codes are a subset of BCH codes with set values dmin = 3 and t = 1. They can detect two errors and correct
one error [44]. Block codes are often expressed in the form (n, k) or (n, k, dmin). A Hamming (3,1,2) code is the
equivalent of a repetition code with each bit sent three times. Table 2 shows examples of the maximum data payload
and correction potential in bits for particular Hamming, Golay and BCH codes. Hamming (7 4 3) and BCH ( 15 5 7)
codes are for the shortest packets (4 and 5 bits respectively) and we will not use these. We are interested in modelling
those codes that can be used for a data payload of 7 or 8 bits and can correct 1, 2 or 3 errors. These are Hamming (15
11 3), BCH (15 7 5) and Golay (23 12 7).
3.2. Error Correction Overhead
The more errors an FEC can correct, the greater the cost in additional processing load, longer packets and increased
transmission time. With a Hamming (15 11 3) code the minimum number of additional error correction bits for an
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S1S2 H1C1 H2H3H4 C2A1A2A3A4A5A6
S2 = Stop Bit S1 = Start BitA1 – A6 = Address  Bits
H1 – H4 = Hamming Correction Bits
C1 – C2 = Command Bits
Figure 5: Drug-delivery data packet with command and error correction.
8-bit data message is 4 bits and the total packet length (including start and stop bits) is 14 bits, as shown in Fig. 5.
The overhead to data ratio is 6/8 or 75% and the packet will have a transmission time of at least 70 ms. The BCH (15
7 5) and Golay (23 12 7) have overhead to data ratios of 142% and 162.5% with transmission times of 85 ms and 105
ms. The larger overall packet size could increase the probability of a loss of synchronisation between the sender and
receiver clocks.
3.3. Coding Gain
The coding gain of an FEC is the effective improvement in bit error rate (BER) resulting from the use of a
particular code on a noisy communications channel. In order to compute the coding gain we must first compute the
uncoded BER for CAP transmission along a vagus nerve that has AWGN. The BER measures the probability of data-
detection errors occurring as the SNR decreases and is based on the complementary error function (erfc) [45], the
probability that a “0” is detected instead of a “1” or vice versa. The total probability of bit error for an uncoded OOK

















The uncoded BER is shown as a surface plot in Fig. 6 across a range of noise levels and a transmission range of 100











where the codeword length is n, the number of data bits is k and the coding rate is k/n. We then use the values of


















The coding gain is a measure of the difference in SNR between uncoded and coded systems for the same BER. The
BER is normally plotted against SNR in dB but in our model it can also be plotted against transmission range. The
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Figure 6: BER for vagus nerve CAP showing increase with noise level and SNR for a transmission range of 100 mm.
Table 3: ATP Code Gain and Parity Bit Cost
BER Uncoded Gain ATP Gain ATP Cost
mm mm nJ nJ
10−10 13 20 920 2392
10−8 31 19 874 5704
10−6 56 16 736 10304
10−4 90 13 598 16560
BER plot for our neural transmission system between uncoded data, Hamming (15 11 3), BCH (15 7 5) and Golay
(23 12 7) coded data is shown in Fig. 7 for noise levels of 5 µV and 10 µV . The curves show that with FEC (i) a fixed
BER can be achieved at a greater range and (ii) a fixed range can have a lower BER.
The plots show that at the lower noise level of 5 µV there is coding gain up to the maximum range of 100 mm. At
the higher noise level of 10 µV there is no coding gain after 30 mm range because of the high BER. The Hamming
(15 11 3) gain can also be expressed in terms of ATP, calculated from the coding gain in mm. This ATP gain must be
offset against the extra ATP needed to carry the corresponding 4 parity bits. Levels of ATP Hamming (15 11 3) gain
and the corresponding ATP parity bit cost is shown in Table 3. In every case the ATP cost is greater than the ATP
gain, and the difference increases with range. FEC can produce gains and improvements in performance in our neural
transmission model but the benefits are sharply reduced with increasing noise level.
4. Drug-delivery System
The embedded drug-delivery system that receives the data packets will have (i) an electrode attached to the vagus
nerve near the brain stem to detect the CAP pulse, (ii) an amplification and conversion system to boost the signal
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Figure 7: BER plots against transmission range for three different types of FEC and two levels of noise.
power and create a digital bitstream, (iii) a microcontroller unit (MCU) to collect and interpret the bitstream, (iv)
a drug-delivery mechanism and addressable reservoirs to respond to processor instructions and (v) a power source
sufficient to meet all energy demands. The addressable reservoirs could be distributed to different parts of the brain,
delivering targetted brain-tumour therapy to locations identified by brain-scans as shown in Fig. 8. A controllable
implanted device make it easier to vary different input parameters but the goal is to develop closed-loop systems that
can record diagnostic requirements and use this as feedback to adjust the drug-delivery instructions.
CAP detection is through a front-end single-channel, single-electrode system similar to those used at present for
recording neural activity [47]. The detected pulses will be in the microvolt range. This low voltage is insufficient to
switch a transistor directly (with existing CMOS technology) and must be amplified and analysed before it can be
designated a logic “1”. The detection and amplification function alone places a minimum requirement on the power
needed to operate the receiving system, without considering the follow-on drug-delivery functions.
4.1. Detection Electrode and Signal Amplification
The CAP detection electrode must be in close proximity to the transmitting nerve and may be wrapped around it
as a cuff electrode. The tripolar nerve cuff electrode design is considered the optimum for low-noise measurement
of peripheral nerve activity. Design principles for recording with tripolar cuff electrodes are given by Loeb and Peck
[47]. The electrical potentials are differentially measured between a single middle contact and two electrically-shorted
symmetrical side contacts. This eliminates any voltage drop (i.e., external noise) that is generated along the inside of
the nerve cuff. The length of a tripolar electrode is typically from 15 mm to 30 mm [48].
The cuff electrode must be connected to a low-noise preamplifier to boost the detected CAP signal. The amplified
signal can then be sent through filters to a comparator for conversion to logic “1” or “0” using an appropriate sampling
rate, and detection threshold set between the noise floor and the expected maximum amplitude. Suitable filters can
remove unwanted higher frequency components from the signal as well as having a role in pulse shaping. Single-
channel and multi-channel neural amplification and digitalisation is described by Muller et al [49] and their system
has a power consumption of 5 µW. Other comparable neural amplifier systems are reviewed in [49] and the power
consumption is also in the low microwatt range.
4.2. Microcontroller Unit
The MCU provides the processor functionality to decode the incoming raw bitstream from the comparator and
perform any error corrections. The architecture of a comparable MCU is described by Huang et al [50] for an im-
plantable drug-delivery system. This has a universal asynchronous receiver/transmitter (UART) to convert serial bits
into parallel, a clock input for timing and a decoder to format and forward commands. The power consumption of the





MCU and Glucose Harvester
Cuff Electrode
Data Packet from Stimulus Array
Drug-release
Command
Figure 8: Distributed drug-delivery at multiple locations in the brain.
4.3. Drug-delivery Function
Electrophoretic drug-delivery, as described by Proctor et al [19], applies a voltage difference (typically 1 V) to
pump ions from a reservoir across an ion exchange membrane using a microfluidic ion pump (µFIP). The amount of
drug delivered depends on the length of time that the voltage is applied. A single type of drug was delivered in trials
and the system is being extended for multiple delivery channels that can be singly activated. The operating voltage (1
V) is low and this would indicate a low power requirement.
An alternative method, electrothermal membrane activation, was first proposed by Santini et al [20] for multiple
drug-delivery. A metallic membrane covering each drug reservoir is heated by an applied electrical current, the
membrane ruptures and the drug reservoir then releases its contents. This release model is used by Huang et al[50] in
a fabricated delivery system that has a total volume of approximately 30 mm3.
The power dissipated will depend on the specific materials used in the membrane and the maximum values of
current and voltage that can be applied. The activation current in [51] has a nominal value of 1 A and is applied for
10 µs resulting in an activation energy of 25 µJ. A lower activation current with a maximum value of 45 mA is used
in [50], applied for 100 ms, results in an activation energy of 6.75 mJ. The power level in both cases would be in the
milliwatt range.
4.4. Drug-delivery Activation Commands
The drug-delivery system in[50] has eight addressable reservoirs. Drug release is activated by a ten-bit OOK
command that consists of start and stop bits, a five-bit activation key and a three-bit address. The authors state that a
more robust forward error correction system would be required in future models.
4.5. Receiver Powering
The electrode, amplification and processor systems will require constant power as they will have to be always-on.
The drug delivery function of the implant will have an intermittent and short duration power requirement. Biological
energy harvesting could provide a biocompatible and long-life method for delivering the necessary power. A fuel cell
using glucose from cerebrospinal fluid circulating around the brain is described by Rapoport et al [52]. The fuel cell
has a roughened platinum anode separated from a carbon nanotube cathode by a cation-selective membrane. Glucose
is oxidised at the anode while oxygen is reduced to water at the cathode. The authors note that the efficiency of
different types of glucose cells varies from 8% to 80%.
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Figure 9: Glucose flux requirement for different power levels at a range of conversion efficiencies.
The glucose flux Jg in milligrams per second (based on 180 mg of glucose per mole) needed to produce a particular





where the conversion efficiency is η and the energy released per mole is ∆Gg = 2880 kJ. The flux of glucose, in
milligrams per second, needed to produce a range of power levels at different conversion efficiencies based on (12) is
shown in Fig. 9. A power level of 10 mW would require flux levels between .00078 mg/s and .000078 mg/s depending
on the efficiency η. The corresponding amount of glucose per day needed to produce a continuous power level of 10
mW ranges from 67.5 mg to 675 mg. The daily flow of glucose through the cerebral space is between 250 mg and 440
mg, so the production of higher levels of power could have a major impact on the glucose levels of the cerebrospinal
fluid especially at low conversion efficiency levels. The Rapoport fuel cell has power density of .034 µW per mm2 in
a steady state and 1.8 µW per mm2 in a transient state with an open-circuit voltage of 192 mV.
Improvements in glucose harvesting performance have been demonstrated by Kwon et al [53] who developed a
hybrid biofuel cell that uses a metallic cotton fibre cathode and has a power density of 37 µW per mm2. A dual-source
glucose and thermoelectric harvesting system is proposed by Katic et al [54] to improve reliability. The system has a
maximum output power of 66 µW. These levels in the microwatt range may be sufficient to power the amplification
and MCU components of a drug-delivery system especially if lower-power and lower-voltage electronic technologies
emerge, like those described by Theis and Solomon [55]. There would, however, need to be power density into the
milliwatt region if drug release using electrothermal membrane activation is to be achieved. Electrophoretic drug
delivery might be a more achievable alternative if the voltage level of a glucose powered system could be boosted
to 1 V using a step-up converter of the type described by Jayaweera et al [56]. Either way, more efficient glucose
harvesting systems would be required if a fully self-powering system is to be realised.
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5. Conclusions
Using the vagus nerve for the transmission of digital CAP pulses is an advancement on existing therapeutic neu-
rostimulation. The left branch of the vagus nerve can be accessed at the neck and is at a shallow enough depth to allow
ultrasound pulses to penetrate and activate a neural stimulus array. The stimulus pulses travel towards the brainstem
and can be intercepted by a receiving electrode and a drug-delivery system. The maximum OOK bit rate of 200 bit/s
is constrained by the neural refractory period and the transmission range would typically be between 60 mm and 100
mm
Our unidirectional, asynchronous transmission system would use short packets to maintain synchronisation at both
ends. Since there is no return path, there is a need to detect and correct data errors at the receiving end. We modelled
the use of block codes for FEC, such as Hamming and BCH, to improve performance. The addition of extra parity
bits increases the total packet length, transmission time and ATP consumption. FEC does provide measurable coding
gains in our model but these become less significant at greater transmission ranges and lower SNRs (higher noise
levels). Simple one-byte (8-bit) commands with additional FEC parity bits can activate an embedded drug-delivery
system near the brain. The packet transmission time of tens of milliseconds is an acceptable timeframe in relation to
the diffusion and absorption time of a drug in brain tissue.
Existing drug-delivery implants require power in the milliwatt range and voltage levels of 1 V or greater. At
present these requirements are met by long-life batteries. Energy harvesting to recharge the battery, using EM systems,
has range and safety constraints. We believe that biological energy harvesting using, for example, glucose in the
cerebrospinal fluid would be a preferable solution in the longer term. There would need to be major improvements
in the power density of the glucose harvesting system and reductions in the power and voltage requirement of the
implanted device before such a system would be feasible.
Implanted devices in the future are likely to be deployed at the micro and nano scale with a consequent need for a
wider range of non-EM communications systems as described by Akyildiz et al [4]. These nanonetworks of devices
will use neural or molecular (chemical) methods of communication within the body and will form part of an Internet
of Things (IoT) healthcare system as described by Dhanvijay and Patil [57]. CAP data communications along different
peripheral nerves could provide an important longer-range transmission option for implant networks, linking clusters
of diagnostic and therapeutic nanodevices to gateway points for communicating to and from external processors.
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